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1 0 0 however, ZIKV infection has been associated to congenital malformations, including 1 0 1 microcephaly, and Guillain-Barré syndrome (GBS), based on clinical and laboratorial 1 0 2 data (7, 8) . Consequently, the World Health Organization (WHO) declared ZIKV 1 0 3 infection as a public health emergency of international concern. Antiviral treatments 1 0 4 against ZIKV are therefore necessary, because they could not only mitigate ZIKV 1 0 5 morbidities but also impair chain of transmission and possess prophylactic activity. teratogenic (9, 10) . Currently, at least three studies have been published in the field of 1 0 9 small molecules inhibitors of anti-ZIKV replication (11) (12) (13) . In these studies, the 1 1 0 authors used in their experimental infections the African ZIKV (ZIKV AFR ) as a 1 1 1 prototype (11) (12) (13) . Importantly, it has been shown that ZIKV AFR is more virulent than 1 1 2 the ZIKV strain circulating in Brazil (ZIKV BRA ) (14), meaning that one might neglected ZIKV replication (11). Whether chloroquine main mechanism of action relates to the 1 1 7 blockage of viral life cycle or promotion of cellular defenses needs to be detailed (11). nucleoside analogs (12, 13) . As these last two works have focused on novel molecules, 1 2 0 extensive pre-clinical studies must be carried out before the translation of their data into 1 2 1 conserved over members of the Flaviviridae family, around 80 % (34). The region 2 9 5 encoding for the C-terminal portion of Flaviviridae RNA polymerase contains around 2 9 6 the 800 amino acid residues and identical residues are highlighted in yellow 2 9 7 (Supplementary Material 1). The residues critical for RDRP activity are conserved 2 9 8 among different viral species and strains, including: ZIKV African strain from the 50's Based on the HCV RNA-direct RNA-polymerase domain, we constructed a 3D 3 0 2 model for ZIKV orthologue enzyme (Figure 1 ). Sofosbuvir was located among the palm 3 0 3 and fingers region of ZIKV RNA polymerase ( Figure 1A) , an area important to 3 0 4 coordinate the incorporation of incoming nucleotides into the new strand of RNA (34). Consequently, amino acid residues relevant to sofosbuvir interaction are some of those 3 0 6 critical for natural nucleotide incorporation and thus RDRP activity ( Figure 1B ) (34). The amino acid residues involved with the interaction with sofosbuvir are identical or The conserved residues are considered to be evolving slower than other residues of this 3 1 0 enzyme (Supplementary Material 2). These information mean that residues predicted to 3 1 1 be required for interaction with sofosbuvir tend to be conserved among members of 3 1 2 Flaviviridae family. modeling prediction that sofosbuvir docked onto ZVRP structure and, reveled that 3 2 1 sofosbuvir chemical structure inhibits ZIKV RDRP activity. Sofosbuvir phosphoramidate prodrug must be converted to its triphosphate analog 3 2 4 within the cellular environment to become active. Therefore, we investigated whether 3 2 5 sofosbuvir inhibits ZIKV replication in cellular systems. Before that, we isolated a 3 2 6
Brazilian ZIKV strain from a confirmed case of zika fever and characterized this isolate (CPE) were detected in BHK-21 cells ( Figure S1 ). Another concern was to stablish 3 3 0 whether other plaque-forming viral agents was co-isolated, which could be misleading 3 3 1 to interpret the antiviral activity. Metagenomic analysis reveal that ZIKV was the only After the characterization of a Brazilian ZIKV strain for experimental virology 3 3 5 assays, we evaluated the ZIKV susceptibility to sofosbuvir. BHK-21, Vero or human inhibition of ZIKV replication ( Figure 3A and B, Table 1 and Figure S2 ). Potency and 3 4 0 efficiency to inhibit ZIKV replication were higher in SH-Sy5y than BHK-21 cells 3 4 1 ( Figure 3A and B, Table 1 and Figure S2 ). Of note, over 10 μM of sofosbuvir did not replication ( Figure 3A and B, Table S1 and Figure S2 ). Sofosbuvir cytotoxicity was also cell type-dependent (Table 1) sofosbuvir varied from 185 to 653 (Table 1) -being safer at MOI equals to 0.5 in the 3 4 9 neuroblastoma cell line. For comparisons, SI values for sofosbuvir were up to 5 times 3 5 0 higher than for ribavirin (Table 1) . Our data point out that that sofosbuvir chemical 3 5 1 structure is endowed with anti-ZIKV activity and efforts to promote its broader considered to be a virus causing only mild and self-limited infections (6). However, based on clinical evidence and laboratorial data, ZIKV infection was associated with 3 6 0 neurological-related morbidities, with impacts on the development of human nervous 3 6 1 system and triggering of GBS (7, 8, 14, (36) (37) (38) (39) . Antiviral treatment options are thus 13). Here, we show that the clinically approved uridine nucleotide analog anti-HCV 3 6 5 drug, sofosbuvir, is endowed with anti-ZIKV activity. replication in Vero cells, which produce high virus titers, and relevant cellular models for studying ZIKV neurotropic replication were evaluated. The African ZIKV isolate 3 7 1 used, which is differently than the one circulating currently. Besides, chloroquine's 3 7 2 potency over ZIKV replication is around 10 μM, whereas against different species of 3 7 3
Plasmodim it acts at the sub-micromolar range. This means that the 500 mg chloroquine tablets approved for clinical use to treat malaria might not be enough to treat ZIKV 3 7 5 infection. The mechanism by which chloroquine inhibits ZIKV replication has not been clinically approved drugs, pointing out to another novel molecule (13). In these 3 8 3 studies, the authors also used the African ZIKV strain and the pharmacological 3 8 4 activity has not been characterized in neuronal cell lines. As these works have focused 3 8 5 on novel molecules, the translation of their data into clinical trials will require further 3 8 6 extensive studies. Sofosbuvir chemical structure is endowed with anti-ZIKV activity, by different 3 8 8 approaches we observed that. Predicted ZVRP structure suggest that sofosbuvir required 3 8 9 critical amino acid residues for ribonucleotide incorporation, such as Arg473, Gly538,
Trp539, Lys691. These results could anticipate that genetic barrier for antiviral 3 9 1 resistance would be high. That is, changes in these residues would jeopardize enzyme 3 9 2 activity. Such a high genetic barrier is found to the emergence of sofosbuvir-resitant 3 9 3 strains of HCV (34). The fluoride radical in sofosbuvir rybosil moiety is coordinated by 3 9 4 the Asn612, an interaction involved with the drug selectivity to RDRP, which may 3 9 5 avoid unspecific effects towards the cellular DNA-dependent RNA-polymerase. The 3 9 6
Lys458 seems to be the docking residue for the uridine analog. Further enzymatic 3 9 7 studies with site-directed mutagenesis to this residue could confirm its participation for 3 9 8 sofsobuvir docking. Sofosbuvir produced a dose-dependent inhibition of ZIKV replication with 4 0 0 different magnitudes in terms of potency and efficiency in BHK-21 and SH-Sy5y cells. Of note, although we succeed to determine the sofosbuvir antiviral activity peripheral organs, such as in spleen and liver (12, (44) (45) (46) . We believe this could be an before its systemic spread. Indeed, it has been reported for some ZIKV-infected patients are urgent. Our data reveal that a clinically approved drug is endowed with antiviral 
